Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
long-acting PYY receptor agonist
- Development stage
- Preclinical
- Lead developer
- i2o Therapeutics
- Modality
- Peptides
- Administration
- Subcutaneous, Oral
01
Overview
i2o Therapeutics' Long-Acting PYY Receptor Agonist is a peptide-based biologic designed to target the Peptide YY (PYY) receptor to suppress appetite and support metabolic regulation. The asset was acquired from Intarcia Therapeutics as part of a broader cardiometabolic pipeline acquisition. It is being developed for the treatment of obesity and cardio-renal-metabolic diseases, with potential utility in type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). The drug utilizes i2o's proprietary ionic liquid technology platform, which is designed to enable long-acting and potentially orally deliverable formulations of peptide therapeutics.
- Other names
- Long-Acting PYY RALong-Acting Peptide YY Receptor Agonist
02
Targets
NPY2R (Neuropeptide Y receptor subtype 2)NPY4R (Neuropeptide Y receptor type 4)PYY receptor (Peptide YY receptor family)
Beyond the preview
Go deeper on long-acting PYY receptor agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on long-acting PYY receptor agonist.